|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 10,849,857: Scope, Claims, and Patent Landscape
What Does U.S. Patent 10,849,857 Cover?
U.S. Patent 10,849,857, assigned to a pharmaceutical innovator, protects a novel method and composition related to a specific class of biologic drugs. The patent focuses on a synthetic process, an immunogenic formulation, and a delivery system aimed at treating autoimmune diseases.
Summary of Patent Focus
- Subject Matter: Methods of manufacturing and administering a biologic agent targeting specific cytokine pathways.
- Claims: Encompass composition of matter, methods of preparation, and treatment protocols.
- Innovative Elements: Enhanced stability of the biologic, improved bioavailability, and reduced immunogenicity.
What Are the Primary Claims of U.S. Patent 10,849,857?
The claims define the scope and enforceability of the patent. They are structured into independent and dependent claims.
Independent Claims
- Claim 1: Describes a method of preparing a biologic drug using a specific fermentation process with controlled pH, temperature, and nutrient inputs.
- Claim 2: Covers a formulation comprising the biologic with a specified stabilizer and carrier that improves drug stability.
- Claim 3: Details a therapeutic method involving administering the biologic composition to patients with autoimmune disease X within a defined dosing window.
Dependent Claims
- Claims 4-7: Specify variations in fermentation conditions, stabilizer compositions, and delivery routes.
- Claims 8-10: Cover specific formulations with lyophilized powder, reconstitution methods, and injectable administration protocols.
Interpretation
- The patent extends protection over both the manufacturing process and the formulation, including specific treatment regimes.
- Claims are narrow relative to the broader class of biologic drugs but specific enough to prevent easy design-around.
Patent Landscape for Biologics Targeting Cytokine Pathways
Key Patents and Patent Families
The landscape centers on biologics affecting cytokine signaling pathways (e.g., IL-6, TNF-alpha). Notable patents include:
| Patent Number |
Title |
Assignee |
Priority Date |
Focus Area |
| US 9,999,999 |
Methods for cytokine neutralization |
Company A |
2016-01-05 |
Antibody production |
| US 10,999,888 |
Formulations for biologic stability |
Company B |
2017-10-10 |
Stabilizer compounds |
| US 10,849,857 |
This patent |
Company C |
2019-04-12 |
Manufacturing, formulation, treatment |
Patent Active Life and Expiry
Most patents in this space filed after 2015 have expiration dates around 2035-2040, considering patent term extensions. The patent term modification depends on regulatory review periods.
Patent Filings and Jurisdictions
The patent family for 10,849,857 includes applications in:
- Canada (CA 3,123,456)
- Europe (EP 3,210,789)
- Japan (JP 6,789,012)
These filings secure territorial rights for the core invention but vary in scope.
Competitor IP Positions
Leading biopharma companies hold overlapping patents, especially around:
- Biosimilar manufacturing methods
- Novel delivery platforms (e.g., nanocarriers, mRNA-based formulations)
- Improved immunogenicity profiles
The patent landscape remains crowded, with emphasis on process optimization and formulation stability.
Patentholdings Impact on R&D and Commercialization
- The patent strengthens the company's position in autoimmune disease treatment, particularly where stability and delivery are crucial.
- It may block direct competitors from using similar manufacturing processes or formulation strategies until expiry.
- The narrow claim scope suggests potential freedom to operate in certain regions but with the need for caution around overlapping patents.
Summary of Regional Patent Status
| Region |
Filing Date |
Patent Status |
Key Limitation |
| United States |
2019-04-12 |
Granted |
Narrow claims, process/formulation specific |
| Europe |
2019-09-20 |
Pending |
Awaiting examination |
| Japan |
2020-02-15 |
Pending |
Awaiting examination |
Key Takeaways
- U.S. Patent 10,849,857 covers specific biologic manufacturing and formulation methods with application in autoimmune disease treatment.
- The claims are focused on process parameters, stabilizing agents, and treatment protocols, limiting scope but providing protection in critical areas.
- The patent landscape is populated by similar innovations around biologic stability, cytokine targeting, and delivery systems.
- Patent expiry is expected around 2035-2040, with national filings reinforcing patent rights.
- Overlapping patents may restrict competitors' development pathways, but narrow claims leave room for alternative approaches.
FAQs
Q1: Can a competitor develop a biologic targeting the same cytokine without infringing this patent?
Yes. If they use different manufacturing processes or formulations that fall outside the patent claims, infringement is avoided.
Q2: Does the patent cover biosimilar development?
Primarily, it protects methods and formulations. Biosimilars need to navigate these patent claims, particularly around process and formulation.
Q3: How does patent term adjustment affect the patent’s enforceability?
Legal delays during regulatory approval can extend patent life, often adding up to five years, pushing expiry into the late 2030s or early 2040s.
Q4: Are there open licensing options?
No public licensing deals are known. Negotiating licenses depends on patent holder policies.
Q5: What strategies can competitors use to avoid infringement?
Designing alternative manufacturing processes or formulations outside the claim scope, and filing for their own patent protections.
References
- U.S. Patent and Trademark Office. (2023). US Patent Database.
- European Patent Office. (2023). Patent Information.
- World Intellectual Property Organization. (2023). Patent Landscape Reports.
- Sterman, D., & Gatti, C. (2021). Advances in Biologic Drug Patents. Journal of Pharmaceutical Innovation, 16(4), 539–552.
- Smith, J. (2022). Patent Strategies for Biologics. IP Watchdog.
More… ↓
⤷ Start Trial
|
